Statin intolerance limits many patients from achieving optimal low-density lipoprotein cholesterol concentrations.
Alirocumab reduced low-density lipoprotein cholesterol levels more than ezetimibe in statin-intolerant patients.
Alirocumab led to fewer skeletal muscle adverse events compared with atorvastatin.